You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response

Article info

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response

Authors

  • Lele Zhang Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, People's Republic of China PubMed articlesGoogle scholar articles
  • Jiacheng Huang Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, People's Republic of China PubMed articlesGoogle scholar articles
  • Xiaona Chen Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, People's Republic of China PubMed articlesGoogle scholar articles
  • Caixu Pan Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, People's Republic of China PubMed articlesGoogle scholar articles
  • Yong He Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China PubMed articlesGoogle scholar articles
  • Rong Su Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, People's Republic of China PubMed articlesGoogle scholar articles
  • Danjing Guo Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, People's Republic of China PubMed articlesGoogle scholar articles
  • Shengyong Yin Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, People's Republic of China PubMed articlesGoogle scholar articles
  • Shuai Wang Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, People's Republic of China PubMed articlesGoogle scholar articles
  • Lin Zhou Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, People's Republic of China PubMed articlesGoogle scholar articles
  • Jianxiang Chen College of Pharmacy, Hangzhou Normal University Hangzhou School of Medicine, Hangzhou, Zhejiang, ChinaDepartment of Hepatology, Hangzhou Normal University Affiliated Hospital, Hangzhou, Zhejiang, China PubMed articlesGoogle scholar articles
  • Shusen Zheng Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, People's Republic of China PubMed articlesGoogle scholar articles
  • Yiting Qiao Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, People's Republic of China PubMed articlesGoogle scholar articles

Citation

Zhang L, Huang J, Chen X, et al
Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response
Journal for ImmunoTherapy of Cancer 2021;9:e003132. doi: 10.1136/jitc-2021-003132
Online issue publication 
November 02, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.